| Name | 11-[[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one |
|---|---|
| Synonyms |
ethyl)-7-piperidinyl)acetyl)
6H-Pyrido(2,3-B)(1,4)benzodiazin-6-one, 5,11-dihydro-11-((2-((diethylamino)methyl)-7-piperidinyl)acetyl) 6H-Pyrido(2,3-B)(1,4)benzodiazin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro Muscinic acetylcholine rector,Otenzad,Inhibitor,mAChR,inhibit,memory 11-[[2-[(DIETHYLAMINO)METHYL]-1-PIPERIDINYL]ACETYL]-5,11-DIHYDRO-6H-PYRIDO[2,3-B][1,4]BENZODIAZIN-6-ONE 6h-pyrido(2,3-b)(1,4)benzodiazin-6-one,5,11-dihydro-11-((2-((diethylamino)m AF-DX (100-1) otenzad AF-DX 116 11-(2-(2-((Diethylamino)methyl)piperidin-1-yl)acetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazin-6(11H)-one Otenzad, 10 mM in DMSO 11-((2-((Diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-(6H)-pyrido[2.3-b]benzodiazin-6-one NPEC-caged-dopamine 6H-Pyrido[2,3-b][1,4]benzodiazin-6-one, 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro 11-[2-[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazin-6-one AF-DX 116 (Otenzad), M2 antagonist Brn |
| Description | Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
640 nM (M2 muscarinic acetylcholine receptor in rabbit peripheral lung), 386 nM (M2 muscarinic acetylcholine receptor in rat heart)[1]. |
| In Vivo | Otenzepad (0.5, 1 mg/kg, s.c., in rats) significantly improved win-stay acquisition relative to vehicle-injected controls[2]. Otenzepad (2 mg/kg, s.c., in rats) significantly improved retention relative to vehicle controls[2]. Otenzepad (0.3, 1.0, or 3.0 mg/kg, ip, in mice) potentiates the effects of glucose and reverses the effects of insulin on memory[3]. Animal Model: Forty-eight male Long-Evans rats (325-350 g)[2]. Dosage: 0.25, 0.5, 1.0 and 2.0 mg/kg. Administration: S.C. on the dorsum of the neck once. Result: Doses of 0.5 and 1.0 mg/kg significantly improved acquisition relative to vehicle controls, while doses of 0.25 and 2.0 mg/kg had no effect. Animal Model: Adult male Swiss mice (age 60–70 days; weight 25-30 g)[3]. Dosage: 0.3, 1.0, or 3.0 mg/kg. Administration: IP once. Result: Enhanced retention in an inverted-U dose–response manner, with significant enhancement seen at 1.0 mg/kg (U15,15 = 49, p < 0.02, compared with saline-saline-injected control group). |
| References |
| Density | 1.171 g/cm3 |
|---|---|
| Boiling Point | 573.2ºC at 760 mmHg |
| Molecular Formula | C24H31N5O2 |
| Molecular Weight | 421.53500 |
| Flash Point | 300.5ºC |
| Exact Mass | 421.24800 |
| PSA | 74.23000 |
| LogP | 3.21440 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
| Precursor 3 | |
|---|---|
| DownStream 0 | |